These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37316746)

  • 1. Editorial Comment on: The Impact of Programmed Death-Ligand 1 Expression on Mismatch Repair Deficiency and Epstein-Barr Virus Status on Survival Outcomes in Patients with Stage II/III Gastric Cancer After Surgery.
    Yokobori T
    Ann Surg Oncol; 2023 Oct; 30(11):6306-6307. PubMed ID: 37316746
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of Programmed Death-Ligand 1 Expression on Mismatch Repair Deficiency and Epstein-Barr Virus Status on Survival Outcomes in Patients with Stage II/III Gastric Cancer After Surgery.
    Akimoto E; Kuwata T; Shitara K; Kawazoe A; Sakamoto N; Ishii G; Ochiai A; Kinoshita T
    Ann Surg Oncol; 2023 Aug; 30(8):5227-5236. PubMed ID: 36934377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
    Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
    Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
    Pereira MA; Ramos MFKP; Faraj SF; Dias AR; Yagi OK; Zilberstein B; Cecconello I; Alves VAF; de Mello ES; Ribeiro U
    J Surg Oncol; 2018 Apr; 117(5):829-839. PubMed ID: 29534305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship Between Programmed Death Ligand 1 Expression and Other Clinicopathological Features in a Large Cohort of Gastric Cancer Patients.
    Chen X; Zhang H; Wang M; Liu H; Hu Y; Lin T; Chen H; Zhao M; Chen T; Li G; Yu J; Zhao L
    Front Immunol; 2022; 13():783695. PubMed ID: 35401534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.
    Kawazoe A; Shitara K; Kuboki Y; Bando H; Kojima T; Yoshino T; Ohtsu A; Ochiai A; Togashi Y; Nishikawa H; Doi T; Kuwata T
    Gastric Cancer; 2019 Jan; 22(1):69-76. PubMed ID: 29859006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr Virus and PD-L1 in Esophageal and Esophagogastric Junction Cancer: Differences According to Location and Histological Type.
    Ribeiro MB; Marques SB; Soares IC; Pereira MA; Takeda FR; Safatle-Ribeiro AV; Ribeiro U
    J Gastrointest Surg; 2022 Nov; 26(11):2358-2364. PubMed ID: 35668227
    [No Abstract]   [Full Text] [Related]  

  • 8. [Association of status of mismatch repair protein expression and EB virus infection with clinicopathological parameters in 886 gastric adenocarcinoma patients].
    Liu Y; Zang FL; Qiu ZQ; Guo YH; Luo Y; Sun L; Zhao S; Shao B; Liang H; Sun Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):440-448. PubMed ID: 34000774
    [No Abstract]   [Full Text] [Related]  

  • 9. Predictive Biomarkers for Immunotherapy in Gastric Cancer: Current Status and Emerging Prospects.
    Hou W; Zhao Y; Zhu H
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus-associated gastric cancer: disease that requires special approach.
    Ignatova E; Seriak D; Fedyanin M; Tryakin A; Pokataev I; Menshikova S; Vakhabova Y; Smirnova K; Tjulandin S; Ajani JA
    Gastric Cancer; 2020 Nov; 23(6):951-960. PubMed ID: 32514646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
    Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
    Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer.
    Wei XL; Liu QW; Liu FR; Yuan SS; Li XF; Li JN; Yang AL; Ling YH
    Oncoimmunology; 2021; 10(1):1938381. PubMed ID: 34235004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
    Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
    Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.
    Sundar R; Qamra A; Tan ALK; Zhang S; Ng CCY; Teh BT; Lee J; Kim KM; Tan P
    Gastric Cancer; 2018 Nov; 21(6):1064-1070. PubMed ID: 29915957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas.
    Yoon CJ; Chang MS; Kim DH; Kim W; Koo BK; Yun SC; Kim SH; Kim YS; Woo JH
    Gastric Cancer; 2020 Sep; 23(5):780-795. PubMed ID: 32206940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed Cell Death Protein 1 Blockade Elicits Ongoing Remission in 2 Cases of Refractory Epstein-Barr Virus-Associated Metastatic Gastric Carcinoma.
    Masetti M; Lindinger M; Lorenzen S
    Oncol Res Treat; 2022; 45(6):375-379. PubMed ID: 35220300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr Virus Positive Gastric Cancer: A Distinct Subtype Candidate for Immunotherapy.
    Pereira MA; Batista DAM; Ramos MFKP; Cardili L; Ribeiro RRE; Dias AR; Zilberstein B; Ribeiro U; Cecconello I; Alves VAF; Mello ES
    J Surg Res; 2021 May; 261():130-138. PubMed ID: 33429221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions.
    Sasaki S; Nishikawa J; Sakai K; Iizasa H; Yoshiyama H; Yanagihara M; Shuto T; Shimokuri K; Kanda T; Suehiro Y; Yamasaki T; Sakaida I
    Gastric Cancer; 2019 May; 22(3):486-496. PubMed ID: 30264329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
    Zhang L; Wang Y; Li Z; Lin D; Liu Y; Zhou L; Wang D; Wu A; Li Z
    Diagn Pathol; 2021 May; 16(1):38. PubMed ID: 33933102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Perspectives of STING and PD-L1 Expression and Correlation with the Prognosis of Epstein-Barr Virus-Associated Gastric Cancers.
    Sun Q; Fu Y; Chen X; Li L; Wu H; Liu Y; Xu H; Zhou G; Fan X; Xia H
    Gut Liver; 2022 Nov; 16(6):875-891. PubMed ID: 35611665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.